


PHARMACEUTICAL 2018



SOLIGENIX INC. Rank 246 of 349







PHARMACEUTICAL 2018

SOLIGENIX INC.

Rank 246 of 349



The relative strengths and weaknesses of SOLIGENIX INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SOLIGENIX INC. compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 183% points. The greatest weakness of SOLIGENIX INC. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 258% points.

The company's Economic Capital Ratio, given in the ranking table, is -345%, being 68% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	9,416
Cost of Goods Sold	4,310
Intangible Assets	74
Liabilities, Current	3,230
Liabilities, Non-Current	0
Other Assets	23
Other Compr. Net Income	0
Other Expenses	-417
Other Liabilities	0
Other Net Income	30
Property and Equipment	37
Research and Development	5,507
Revenues	5,432
Selling, General and Administrative Expense	3,209

Output Variable	Value in 1000 USD
Assets	9,550
Liabilities	3,230
Expenses	12,609
Stockholders Equity	6,320
Net Income	-7,147
Comprehensive Net Income	-7,147
Economic Capital Ratio	-345%

